Who Generates More Revenue? Novartis AG or BioMarin Pharmaceutical Inc.

Novartis vs. BioMarin: A Decade of Revenue Insights

__timestampBioMarin Pharmaceutical Inc.Novartis AG
Wednesday, January 1, 201475104000053634000000
Thursday, January 1, 201588989500050387000000
Friday, January 1, 2016111685400049436000000
Sunday, January 1, 2017131364600050135000000
Monday, January 1, 2018149121200053166000000
Tuesday, January 1, 2019170404800048677000000
Wednesday, January 1, 2020186045500049898000000
Friday, January 1, 2021184627500052877000000
Saturday, January 1, 2022209603900051828000000
Sunday, January 1, 2023241922600046660000000
Monday, January 1, 202451722000000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Showdown: Novartis AG vs. BioMarin Pharmaceutical Inc.

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Novartis AG and BioMarin Pharmaceutical Inc. have been at the forefront, each carving out a distinct niche. From 2014 to 2023, Novartis AG consistently outperformed BioMarin, generating approximately 30 times more revenue annually. In 2023, Novartis AG reported a revenue of around $46.66 billion, while BioMarin reached $2.42 billion, marking a significant growth of over 220% for BioMarin since 2014. This trend highlights Novartis's dominance in the global market, yet underscores BioMarin's impressive growth trajectory in the biotech sector. As the industry evolves, these figures not only reflect past achievements but also set the stage for future innovations and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025